We're building China's first platform-grade infrastructure rooted in compliance science, with GLP as the hub, spanning the full journey of biopharma and medtech projects from validation to industrialization.
Seno.Bio (Hangzhou Shennong Jiuzhou Biotechnology Co., Ltd.) was founded in April 2022, drawing on the research and compliance resources of Zhejiang University's Institute of Technology Global Medical-Engineering Translation Platform and the Yangtze River Delta National Technology Innovation Center (Zhejiang) Drug Safety Evaluation Institute.
We've built a full-chain platform with GLP compliance validation as its hub, CDMO contract manufacturing as its extension, and commercialization as its outlet to market; for projects with a genuine growth-funding need, we can also participate through Growth Co-Investment.
This system is helping innovative drug and device projects move from proof of concept to full-scale implementation.
China's biopharma industry is entering a period of explosive growth, but the traditional CXO landscape is fragmented and disconnected, lacking an integrated platform that spans validation, compliance, and industrialization. GLP capacity is in serious short supply, drug and device logic remains split apart, and advanced therapy products (cell and gene therapy, tissue engineering) can't find a complete service system to support them.
What happens after a product is registered is a natural extension of what we do. Our partnership with Jointown Pharmaceutical Group (SSE 600998) means devices manufactured on our platform, once registered, can plug directly into its nationwide distribution network — no province-by-province distributor search, no sales infrastructure built from scratch.
For projects that need capital, we can participate through Growth Co-Investment — this means equity investment. It's part of what we offer, not our core business; our core is GLP compliance validation, CDMO contract manufacturing and commercialization.
Safety evaluation, contract manufacturing and platform operations are run by three teams with distinct remits. Here is who does what.
GLP studies are carried out at the Yangtze River Delta National Innovation Centre for Drug Safety Evaluation Technology, within the same national innovation system as the platform. The centre is led by Prof. Liao Mingyang.
Design transfer, process validation, registration testing and licensed production are handled by the platform’s manufacturing operation, and its inspection record and quality system are open to verification.
Commercial terms, contracting, risk control and cross-border liaison sit with the platform’s operating team.